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Abstract: Cancer is the second leading cause of death worldwide. Chemotherapy has shown
reasonable success in treating cancer. However, multidrug resistance (MDR), a phenomenon by
which cancerous cells become resistant to a broad range of functionally and structurally unrelated
chemotherapeutic agents, is a major drawback in the effective use of chemotherapeutic agents
in the clinic. Overexpression of P-glycoprotein (Pgp) is a major cause of MDR in cancer as
it actively effluxes a wide range of structurally and chemically unrelated substrates, including
chemotherapeutic agents. Interestingly, Pgp is also overexpressed in the endothelial cells of
blood–brain barrier (BBB) restricting the entry of 98% small molecule drugs to the brain. The efficacy
of Pgp is sensitive to any impairment of the membrane structure. A small increase of 2% in the
membrane surface tension, which can be caused by a very low drug concentration, is enough to block
the Pgp function. We demonstrate in this work by mathematical equations that the incorporation of
drugs does increase the surface tension as expected, and the mechanism of endocytosis dissipates any
increase in surface tension by augmenting the internalisation of membrane per unit of time, such that
an increase in the surface tension of about 2% can be dissipated within only 4.5 s.
Keywords: multidrug resistance; P-glycoprotein; pinocytosis; cancer; blood–brain barrier impermeability
1. Introduction
Cancer is the second leading cause of death worldwide [1]. It is a major health problem worldwide
with more than 18 million patients diagnosed with cancer in 2018, and a death toll of around 9.5 million.
The incidence rate of cancer is estimated to increase to 24 million new cases in 2030, with 13 million
annual deaths [2]. Chemotherapy has shown reasonable success in treating cancer; for example,
Hodgkin’s lymphoma and paediatric acute lymphoblastic leukaemia were considered uniformly fatal
diseases few decades ago, and today, 75 to 80% of patients are cured using a course of combination
chemotherapy [3]. However, multidrug resistance (MDR) is a major drawback in the effective use of
chemotherapeutic agents in the clinic [4,5]. MDR is a phenomenon by which cancerous cells become
resistant to a broad range of functionally and structurally unrelated chemotherapeutic agents [6].
Cancer cells can develop MDR through different mechanisms, such as decreasing drug uptake,
increasing drug efflux, activation of detoxifying systems and activation of DNA repair mechanisms [7].
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Overexpression of P-glycoprotein (Pgp), also known as ATP Binding Cassette Subfamily B Member 1
(ABCB1) or multidrug resistance 1 (MDR1), is a major cause of MDR in cancer. MDR cell lines
exhibit a reduced intracellular accumulation of drug relative to the parental drug- sensitive cell
lines [8]. Furthermore cancer aggressiveness, i.e., the metastatic potential of tumours, is related to
MDR [9]. Pgp actively effluxes a wide range of structurally and chemically unrelated substrates,
including chemotherapeutic agents. Extensive research has been carried out over the past few decades
to reverse Pgp-mediated MDR. While Pgp inhibitors were successful in resensitising MDR cells to
chemotherapeutic agents in vitro, they failed to show any significant clinical benefit [6].
In addition to its role in cancer, MDR is a significant hurdle to overcome in the development
of effective drugs for central nervous system (CNS) diseases. The lack of effective pharmacological
treatments for diseases of the CNS is a prominent issue within our society; with 1 in 6 people suffering
from a form of CNS disease as of 2019 [10]. The difficulty in designing drugs for CNS diseases is, in part,
due to MDR at the blood–brain barrier (BBB). The BBB controls the transport of critical nutrients and
waste products in and out of the CNS, maintaining the carefully regulated microenvironment required
for neuronal signalling. The continuous monolayer of endothelial cells that line the microvessels
within the CNS forms the BBB through expression of tight junctional adhesion proteins, MDR efflux
transporters and metabolic enzymes. The tight junctions at the BBB eliminates the paracellular diffusion
of drug-like molecules and forces molecules through the transcellular pathway [11]. Molecules are
then forced through the transcellular pathway and are subject to non-specific MDR efflux transporters.
Pgp was the first MDR transporter to be identified in BBB-forming endothelial cells and has been
the most extensively studied [12]. MDR transporters, including Pgp, work in conjunction with tight
junctional adhesion to restrict the entry of 98% of all small molecule drugs, and 100% of all biologics,
to the brain [13].
As a result of the effects on both cancer chemotherapy and CNS drug development, Pgp remains
the archetypical drug transporter whose function needs to be fully elucidated to improve drug efficiency.
Although Pgp has always been considered the centrepiece of MDR in cancer and at the BBB, it has
become clear over the years that, on its own, Pgp cannot fully explain its function as a drug
barrier element. Indeed, it has been shown that the drug-membrane interaction, including the
physicochemical properties of drugs and the biophysical state of the membrane, are essential to support
Pgp function [14–19].
It follows that the efficacy of Pgp should be sensitive to any impairment of the structure that
supports its function. Through proteoliposome studies, it has been deduced that changes in surface
tension of the cell membrane induced by the incorporation of drugs are enough to impede Pgp
function [20]. Experimental results confirming this theory suggest that a small increase in the
membrane surface, of about 2%, is enough to block the effect of Pgp [20]. This conclusion, in turn,
means that even considerably low drug concentrations could affect Pgp function, and therefore,
we hypothesise that there is a biological mechanism in place to protect Pgp efficiency against any
change in the membrane surface tension.
We demonstrate here that a key element protecting Pgp function is pinocytosis, which is also
known as fluid phase endocytosis [21]. Indeed, we demonstrate that the incorporation of drugs does
increase the surface tension as expected, but that the mechanism of endocytosis dissipates any increase
in surface tension by augmenting the internalisation of membrane per unit of time, such that an increase
in the surface tension of about 2% can be dissipated within 4.5 s. We suggest that this mechanism
protects Pgp function and efficiency involved in MDR in cancer chemotherapy and at the BBB.
2. Physical Impact of Drug–Lipid Monolayer Interaction
To simplify the model, let us consider a lipid monolayer of total surface area S and composed
N identical lipids modelled as cylinder each occupying an optimal surface area a0. The variable a0
results from two fundamental properties of lipids linked to their amphipathic nature and we aim to
determine an expression of a0 as a function of basic physicochemical properties of lipids. To achieve this,
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we consider the hydrophobic part of the lipids and introduce a penalty energy, i.e., positive energy,
linked the surface area per lipid. To visualise this penalty energy, let us imagine that the total surface
area of the leaflet is increased, for example by ‘pulling’ the leaflet laterally, then as the leaflet surface area
contains a constant number of lipids, expending the leaflet is only possible if the surface area available
per lipid increases as well. However, when the distance between lipids increases, water molecules
can penetrate the leaflet and interact with the hydrophobic part of the lipids that, in turn, is not
favoured (Figure 1A). As a result, one can define this penalty energy as being proportional to the
surface area of lipids under the form ∼ λa where λ is a positive constant and a is the surface area per
lipid (Figure 1A). The latter energy stipulates that any increase in the surface area per lipid provides a
(positive) penalty energy. If this was the only energy term considered, then the membrane should
shrink totally to impose a ∼ 0. However, this is not possible due to steric repulsions between lipids
and therefore the shrinkage has limits. In this context, one introduces a second energy term stating
that when a tends towards zero a penalty energy occurs under the form ∼ µ/a where µ is also a
positive constant resulting from lipid–lipid repulsion (Figure 1A). As a result and by definition, as the
energies balance each other when a ∼ a0 the relation that defines a0 as a function of lipids fundamental
physicochemical properties is then λa0 ∼ µ/a0 or equivalently: a0 ∼
√
µ/λ (Figure 1B).Sy metry 2020, 12, x FOR PEER REVIEW 4 of 11 
 
 
Figure 1. (A) Assuming that the membrane leaflet is composed of charged or polar lipids, the optimal 
area per lipid is determined by the competition between an attraction energy and a repulsion energy. 
The attraction energy of the lipid is linked to the physicochemical structure of the head and the 
repulsion energy is linked to their hydrophobic tails. The competition between these two energy 
terms defines a “minimum of energy”. It should be noted that, in the figures, “α” corresponds to the 
optimal distance between adjacent lipid heads. (B) From the illustration in Figure A, we can assume 
that the minimum of energy provides the optimal distance between lipids, including their optimal 
area in the monolayer. It should be noted that the packing of lipids is not always defined by hard-
core contact and that, accordingly, there is room to change this packing. (C) Lipid asymmetry at the 
vesicular scale: given the small size of vesicles, the radius 𝑅௩  and membrane thickness ℎ  are 
different, ோೡ௛ ~10. Thus, the outer leaflet of a vesicle 𝑆ଶ has significantly more lipid than the inner 
leaflet 𝑆ଵ. As the vesicle is assumed to be spherical, and noting that the neutral surface area between 
the outer and inner leaflets: 𝑆଴ = 4𝜋𝑅௩ଶ that does not change upon membrane budding, it follows at 
the first order that 𝑆ଶ = 4𝜋ሺ𝑅௩ + ℎ/2)ଶ~𝑆଴ሺ1 + ℎ/2𝑅௩)ଶ  and 𝑆ଵ = 4𝜋ሺ𝑅௩ − ℎ/2)ଶ~𝑆଴ሺ1 − ℎ/2𝑅௩)ଶ . 
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area per lipid is determined by the competitio etween an ttraction energy and a repulsion energy.
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The attraction energy of the lipid is linked to the physicochemical structure of the head and the
repulsion energy is linked to their hydrophobic tails. The competition between these two energy terms
defines a “minimum of energy”. It should be noted that, in the figures, “α” corresponds to the optimal
distance between adjacent lipid heads. (B) From the illustration in Figure A, we can assume that the
minimum of energy provides the optimal distance between lipids, including their optimal area in the
monolayer. It should be noted that the packing of lipids is not always defined by hard-core contact
and that, accordingly, there is room to change this packing. (C) Lipid asymmetry at the vesicular
scale: given the small size of vesicles, the radius Rv and membrane thickness h are different,
Rv
h ∼ 10.
Thus, the outer leaflet of a vesicle S2 has significantly more lipid than the inner leaflet S1. As the
vesicle is assumed to be spherical, and noting that the neutral surface area between the outer and inner
leaflets: S0 = 4piRv2 that does not change upon membrane budding, it follows at the first order that
S2 = 4pi(Rv + h/2)
2 ∼ S0(1 + h/2Rv)2 and S1 = 4pi(Rv − h/2)2 ∼ S0(1− h/2Rv)2. (D) A schematic to
link fluid phase endocytosis to membrane phospholipid asymmetry: In the left panel, the translocation
of dark-headed lipids into the inner leaflet induces a differential packing of lipids between leaflets.
This leads to membrane bending and vesiculation [21]. It should be noted that membrane recycling
(i.e., the exocytosis of vesicles of a size similar to endocytic vesicles) occurring in cells allows the
maintenance of the lipid asymmetry, and thus, the maintenance of differential packing of leaflets at the
level of the plasmalemma (shown in right panel). The relationship existing between the lipid number
asymmetry and the vesicle radius is given by
(
h
2RV
)
0
=
(
2λ δNN
)
/
(
2kc
h2
)
. Lipid number asymmetry has
been experimentally deduced from studies on drug sensitive cells (K562), with a value δNN ∼ 2% ,
providing a ~ 35 nm vesicle radius [21].
To summarize, the total energy per lipid, or lipid physicochemical potential, is given by∼ λa+µ/a
and the energy of the leaflet is then the energy per lipid multiplied by the number of lipids composing
the leaflet ∼ N(λa+ µ/a).
Let us now assume that drugs incorporate into the leaflet and that the surface area of the leaflet
is fixed. It is then expected that the incorporation of drugs will have an impact on the optimal
surface area per lipids, transforming a0 to a0 + δa where δa < 0 is the variation in the surface area
per lipid due to the presence of drugs in the membrane. Note that δa < 0 as drugs are expected
to compress the lipids of the leaflet. In any case, the energy of the leaflet can be rewritten as
∼ N(λ(a0 + δa) + µ/(a0 + δa)); but if one assumes that the relative compression is small, in that
δa/a0  1, then the energy of the leaflet can be developed mathematically up to the second order
as: ∼ Nλa0 + Nλa0 δaa0 + N
µ
a0
−N µa0 δaa0 + N2
µ
a0
(
δa
a0
)2
. The latter expression can then be rewritten as:
∼ N
(
λa0 +
µ
a0
)
+N
(
λa0 − µa0
)
δa
a0
+ N2
µ
a0
(
δa
a0
)2
. The first term, i.e., N
(
λa0 +
µ
a0
)
, is the initial energy of the
leaflet without any drugs, and the second term, i.e., N
(
λa0 − µa0
)
δa
a0
, is null as a0 is defined by λa0 ∼ µ/a0.
As a result, the energy of the leaflet, E, is simply: E ∼ E0 + λNa02
(
δa
a0
)2
; where E0 = N
(
λa0 +
µ
a0
)
corresponds to the initial energy of the leaflet without any perturbation. To express the energy as
a function of the drug concentration in the leaflet, one rewrites the term δaa0 as:
Nδa
Na0
. As the term
Nδa corresponds to the reduction of the surface area of the leaflet, in particular the reduction of
surface area due to the incorporation of drugs, let us assume that ND drugs have incorporated the
membrane and that drugs have a cross section area given by aD, then: Nδa = −NDaD; and as a result:
E ∼ E0 + λNa02
(NDaD
Na0
)2
. As Na0 is the surface area of an unperturbed leaflet the term,
NDaD
Na0
, corresponds
to the surface density of drugs. It is also worth noting here that for drugs that are small enough,
their volume in angstrom units, noted VD, is proportional to their molecular weight: VD ∼ (MW)D;
the cross sectional area of a drug can be rewritten as: aD ∼ α(MW)D2/3 where α is a geometrical factor
given by α =
(
3
√
pi/4
)2/3
for a drug that is assumed to be spherical. Finally, by posing β = λα
2
2 ; and
noting CD =
ND
Na0
the surface concentration of drugs, one deduces:
E− E0 ∼ Na0β(MW)D4/3(CD)2 (1)
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Traditionally CD is determined by the octanol-water partition coefficient of the drug chemical,
and therefore the energy of the leaflet is a function of two well-characterized drug parameters.
Perhaps the most interesting is to note that, as far as the membrane is involved, the drug molecular
weight and its affinity for the membrane are, to some extent, equivalent. Indeed, as far as the leaflet
energy is concerned, and as long as the term (MW)D
4/3(CD)
2 is constant, the energy remains constant.
The next question is to provide a generalization of the development above, while considering the
plasma membrane as a whole and the impact of drugs on membrane vesiculation.
3. Physical Impact of Drug–Membrane Interaction
Let us go back to the leaflet’s energy, but this time considering that the parameter δaa0 results from
two effects: (i) a constant lipid asymmetry linked to the flippase activity and, (ii) the accumulation of
drugs. In this context, we note the inner leaflet as the subscript ‘2′ and the outer leaflet as subscript ‘1′.
Finally, we shall also assume that the drug chemical is small enough to be present in both leaflets in
similar proportion.
The leaflets’ energy are written as: E1,2 ∼ E0 + λNa02
(
Nδa1,2
Na0
)2
, where Nδa1,2 = δS1,2 is the change
in the surface area of either leaflet. However, the later description is valid for ‘flat’ leaflets and does not
consider possible local curvatures, i.e., vesiculation or membrane budding, that are fundamentally
involved in releasing the membrane energy. This is the reason why it is preferable to use a differentiated
form of leaflets’ energy and consider the surface tension of leaflets, noted σ1,2, and defined formally
by: σ1,2 = dE1,2/dS1,2, where ‘d’ means difference. Thus, for either leaflet, σ1,2 is defined as the
surface energy and represents the variation of leaflets energy as function of a change in surface area
of leaflet. In this context, dE1,2 ∼ σ1,2dS1,2 where σ1,2 = λNδa1,2Na0 is the surface tension of either leaflet.
The meaning of the differential form for the leaflets’ energy is slightly different from the leaflet energy
described by Equation (1). Indeed, as any energy state of a physical system has to be as small as
possible, if σ1 < 0 for example, then the energetically favoured state is the one selecting dS1 > 0
that is to say that a compressed leaflet (σ1 < 0) will try to expand (dS1 > 0) such that the energy
variation of the leaflet is negative (dE1 < 0) to become in due course the smallest possible. Let us
consider now the total energy of the membrane, namely the addition of the individual leaflets energy:
dE1 + dE2 = σ1dS1 + σ2dS2, and assume that the total energy is the smallest possible; then in this case
dE1 + dE2 = 0. The latter relation mathematically explains that the membrane energy is the smallest
possible and cannot decrease further. This relation also implies that σ1dS1 + σ2dS2 = 0 or equivalently:
dS1
dS2
= −σ2σ1 . The latter relation is important as it states that as the bilayer membrane is composed of
two sub-systems, i.e., the leaflets, then the only possibility for the bilayer membrane to optimize its
energy is to find a way such as dS1dS2 = −
σ2
σ1
; and one possibility is to create membrane buds (leading to
the formation of vesicles) (Figure 1C,D).
By taking a pool of lipids from the outer leaflet to place it onto the outer leaflet, the flippase
activity compresses the inner leaflet and dilates the outer one to a similar extent without changing the
overall number of lipids composing the bilayer membrane (Figure 1D). Let us note δN the lipid number
asymmetry; one deduces that the relative variation in surface area per lipid in the inner leaflet is − δNN
due to compression and + δNN in the outer leaflet due to dilation. To further consider the presence
of drug chemicals distributing equally between leaflets determines that finally: σ1/λ = − δNN − NDaDNa0
and σ2/λ = + δNN − NDaDNa0 . As a result, the energy of the flat bilayer membrane written as a differential
form becomes:
dE1 + dE2 = σ1dS1 + σ2dS2 = λ
(
−δN
N
− NDaD
Na0
)
dS1 + λ
(
δN
N
− NDaD
Na0
)
dS2 (2)
From Equation (2), one deduces that as σ1 < 0 the inner leaflet will try to expand to verify dS1 > 0.
For the outer leaflet, however, nothing can be considered clear-cut, as this depends on the amount of
drug that is present since σ2 can be either positive or negative as a function of the surface concentration
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of drugs. As the two leaflets are coupled, the expansion or dilation of leaflets can be performed via the
formation of membrane curvature relative to the neutral surface area that is defined as the surface at
the mid-distance between leaflets, namely, the surface separating the two leaflets of the membrane
bilayer (Figure 1C).
Let us consider now that the membrane bilayer starts budding locally, in this case dS1 and dS2
will become a function of the curvature radius of the membrane bud (Figure 1C,D). For small buds,
like vesicles, it is necessary to add a further energy term linked to membrane bending that we shall
note dEc where the subscript ‘c’ refers to cuvature. Using the differentiated form this term is written
as dEc =
kc
2h2
(
h
RV
)2
dS0 where ‘kc’ ‘S0’, ‘h’ and ‘RV’ designate, respectively, the bending modulus of the
membrane, the neutral surface (Figure 1C), the membrane thickness (Figure 1C,D) and the curvature
radius of the membrane bud (Figure 1C,D). As a result, the differentiated form of the total energy,
dEtot = dEc + dE1 + dE2, is:
dEtot =
kc
2h2
(
h
RV
)2
dS0 + λ
(
−δN
N
− NDaD
Na0
)
dS1 + λ
(
δN
N
− NDaD
Na0
)
dS2 (3)
Equation (3) is null namely the membrane bilayer system has found its equilibrium state when
dEtot = 0. As result, the bilayer membrane and related vesicle radius must abide by:
kc
2h2
+ λ
(
−δN
N
− NDaD
Na0
)
dS1
dS0
+ λ
(
δN
N
− NDaD
Na0
)
dS2
dS0
= 0 (4)
Further using dS1dS0 =
(
1 + h2RV
)2
and dS2dS0 =
(
1− h2RV
)2
(see Figure 1C) one deduces:
(
2kc
h2
− 2λNDaD
Na0
)(
h
2RV
)2
− 2λδN
N
(
h
2RV
)
− 2λNDaD
Na0
= 0 (5)
Let us solve the quadratic equation given by Equation (5) one finds:
(
h
2RV
)
=
2λ δNN +
√(
2λ δNN
)2
+ 4
(
2λNDaDNa0
)(
2kc
h2 − 2λ
NDaD
Na0
)
(
2kc
h2 − 2λ
NDaD
Na0
) (6)
Note that quadratic equations bring two solutions, however, in our case Equation (6) is the only
solution possible as when the drugs are absent, but the lipid asymmetry is present, a solution must
exist. Let us note
(
h
2RV
)
0
the solution to Equation (6) when drugs are absent, i.e., for CD = 0, then the
solution is:
(
h
2RV
)
0
=
(
2λ δNN
)
/
(
2kc
h2
)
as determined elsewhere [21].
From Equation (6), one can determine the critical or maximal amount of drugs required to block
or inhibit the endocytic process imposes a vesicle radius that is null. Let us note
(NDaD
Na0
)
M
the critical
surface density of drugs one deduces theoretically:
(NDaD
Na0
)
M
∼ kc
λh2 . Using kc ∼ 10−19 J, λ ∼ 0.2 N·m−1
and h ∼ 5 nm [20] one can estimate:
(NDaD
Na0
)
M
∼ 0.2. This value is 10 times higher than the amount
required to impair the function of the drug transporter Pgp [22].
As a conclusion, by affecting the surface tension, the interaction of drugs with the membrane
decreases the vesicle radius. This point is important as the vesicle radius is directly related to the
kinetics of membrane endocytosis [20]. The next question is to determine whether the presence of drugs
in the membrane perturbs the membrane recycling that, in turn, protects Pgp function and activity.
4. Physical Impact of a Change in Surface Tension on the Kinetics of Membrane Pinocytosis
There is one remark of great importance to be made before clarifying how a change in surface
tension affects the kinetics of pinocytosis. We saw above that once homogenously incorporated
into the membrane, drugs are able change the surface tension. If one assumes that the kinetics
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of pinocytosis are impacted, given that pinocytosis occurs everywhere as the membrane is not
compressible, the amount of surface area leaving the plasma membrane per unit of time will not
uniquely involve drugs. A different way to understand this is to say that drugs in the membrane trigger
an overall response from the plasma membrane, and that the kinetics of pinocytosis, when changed,
will dissipate the excess in surface tension brought initially by drugs. So in this context, instead of
writing ‘NDaDNa0 ’ the excess of surface area of the plasma membrane, one can write it more generically
under the form: ‘ δSNa0 ’ and determine the variation of ‘
δS
Na0
’ as a function of time with the condition that
δS
Na0
(t = 0) = NDaDNa0 . In these conditions, Equation (6) can then be rewritten by replacing ‘
NDaD
Na0
’ by ‘ δSNa0 ’.
To determine ‘ δSNa0 ’ as a function of time, we start by considering the steady state of membrane
recycling and assume that when the membrane is not perturbed the kinetics of endocytosis is identical
to the kinetics of exocytosis. This initial assumption guaranties the balance of membrane being
exchanged and recycled through endocytosis and exocytosis. If there are NV endocytic vesicles, each of
surface area SV, being created from the plasma membrane between the times t and t+ dt, then the
amount of membrane being internalized is NVSVdt/τV; where τV is the characteristic time for a
vesicle to be created. Previous work has demonstrated that the membrane recycling between the
plasma membrane and the intracellular compartments is controlled by the volume exchanged [20],
and that the flow of volume endocytosed must equate the flow of volume exocytosed. A simple way
to understand this principle is to consider a cell with a given volume and imagine that vesicles are
forced to penetrate the cytosol. As each vesicle entering the cytosol needs a free cytosolic volume
equivalent to their own volume, if a fraction of the cytosolic volume was not released by exocytosis
then forcing endocytosis would increase the pressure inside the cells. However, this is not possible
as the cytosol is an aqueous medium with a resulting compressibility that is almost null. Thus, in a
context were cells in tissues maintain their constant volume (as otherwise tissues would swell) the
volume entering the cell per unit of time must be constant, in other words NVVVτV ∼ cte where VV is the
vesicular volume. Noting that RV the vesicle radius, as VV =
SVRV
3 for a spherical vesicle, this principle
allows one to deduce that the kinetics of membrane endocytosis is: NVSVτV ∼ 3RV . Let us now compare
two states, an initial one where the cellular membrane is not perturbed and generates vesicles with a
radius noted (RV)0; and another state where the cellular membrane is perturbed by drugs and as a
result the vesicle radius has changed and is now RV . Then the amount of membrane being internalised
in the latter case can be expressed as a function of the amount of membrane being internalised in the
former case under the form: NVSVτV ∼
(NVSV
τV
)
0
(RV)0
RV
. As a result, the difference in membrane flow is:
NVSV
τV
−
(NVSV
τV
)
0
=
(NVSV
τV
)
0
[
(RV)0
RV
− 1
]
. Consequently, over a time interval ‘dt’ the amount of excess
surface area being removed from the plasma membrane through a change in the kinetics of pinocytosis
is:
[NVSV
τV
−
(NVSV
τV
)
0
]
dt =
(NVSV
τV
)
0
[
(RV)0
RV
− 1
]
dt. This excess being removed from the plasma membrane
will result in a drop of ‘δS’ from ‘δS’ to ‘δS− d(δS)’. As a result, one can deduce a temporal differential
equation for ‘δS’ under the form: −d(δS) ∼
(NVSV
τV
)
0
[
(RV)0
RV
− 1
]
dt. Let us divide the right and left
members by ‘Na0’ and note ‘δS˜ = δSNa0 ’ and δS˜M =
(NDaD
Na0
)
M
∼ kc
λh2 to simplify notations and define,
k0
def
= 1Na0
(NVSV
τV
)
0
as the fraction of plasma membrane surface area being internalized by the process of
pinocytosis per unit of time for an unperturbed membrane, one deduces:(
1− δS˜
δS˜M
)
d
(
δS˜
δS˜M
)

√
1 + 4
(
2(RV)0
h
)2
δS˜
δS˜M
(
1− δS˜
δS˜M
)
+ δS˜
δS˜M

∼ − k0
δS˜M
dt (7)
We note from Equation (7) that in the case where δS˜
δS˜M
 1, i.e.,
(
1− δS˜
δS˜M
)
∼ 1, the fraction of
plasma membrane per unit of time undergoing pinocytosis is similar to the kinetics of pinocytosis if
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4
(
2(RV)0
h
)2
δS˜
δS˜M
 1. The latter inequality allows one to define the lower concentration of membrane
drugs, or the lower excess in surface tension, brought about by the addition of surface area to the
plasma membrane, leading to an increase in the kinetics of pinocytosis. Indeed, by defining ‘δS˜m’
and writing: 4
(
2(RV)0
h
)2
δS˜m
δS˜M
∼ 1; ‘δS˜m’ is then the lower fraction of membrane aforementioned. Let us
assume that a typical vesicle radius is (RV)0 ∼ 50 nm [21], using this radius one finds: δS˜mδS˜M ∼ 1.5·10
−4,
or equivalently δS˜m ∼ 1.5·10−4·δS˜M ∼ 3·10−5, suggesting this is a remarkably sensitive process.
As a result, Equation (7) can be rewritten in the form:(
1− δS˜
δS˜M
)
d
(
δS˜
δS˜M
)
[√
1 + δS˜M
δS˜m
× δS˜
δS˜M
(
1− δS˜
δS˜M
)
+ δS˜
δS˜M
] ∼ − k0
δS˜M
dt (8)
From Equation (8) one sees that, for a physiologically acceptable concentration of drugs when(
1− δS˜
δS˜M
)
∼ 1, the equation can be approximated and solved as:
√
1 + δS˜M
δS˜m
× δS˜
δS˜M
∼ − k0
2δS˜m
t+ K;
where ‘K’ is an integration constant. To determine ‘K’ let us note ‘T’ the time needed to dissipate the
excess in surface tension, which is defined by δS˜(t = T) = 0, then by definition: 1 ∼ − k0
2δS˜m
T + K;
and as a result:
√
1 + δS˜M
δS˜m
× δS˜
δS˜M
∼ 1 + k0
2δS˜m
(T − t). We also recognise that by noting δS˜(t = 0) = δS˜0,
the time ‘T’ needed to dissipate the excess in surface tension is related to ‘δS˜0’ under the form:√
1 + δS˜M
δS˜m
× δS˜0
δS˜M
∼ 1 + k0
2δS˜m
T.
In this context let us assume that δS˜0 ∼ 2%, which is sufficient to block Pgp function [22], then:
δS˜M
δS˜m
× δS˜0
δS˜M
∼ δS˜0
δS˜m
∼ 666 1; using k0 ∼ 2% min−1 typically [21] one deduces: T ∼ 4.5 s .
As a result, the time ‘T’ needed to dissipate the excess in surface tension is remarkably short amid
to the sensitivity of pinocytosis and as a result Pgp function and activity is protected by the membrane.
5. Discussion and Conclusions
Much of the work around MDR in cancer chemotherapy, or CNS drug resistance at the BBB,
revolves around the notion of efflux by drug transporters. Pgp is the archetypal MDR transporter,
as it has been extensively studied in both physiological cases [6,13]. However, many works have
determined that Pgp on its own is not sufficiently responsible for drug efflux, as the experimental
data obtained seems contradictory [16,17,23]. One aspect that has attracted our attention concerns the
experimental fact that a relatively small increase in the surface tension of the cell membrane (around 2%)
through drug accumulation can block Pgp function [21]. This impairment of Pgp function and activity
is primarily linked to the physicochemical properties of the drug, including the octanol–water partition
coefficient, the drug molecular weight, and consequently, their affinity to the plasma membrane.
Therefore, the key question was to determine what biological process could be in place to maintain
Pgp function, as the critical 2% increase in surface tension is largely expected to occur at relatively low
physiological concentrations of drug. In turn, we have determined that the mechanism of pinocytosis
(fluid-phase endocytosis) acts to dissipate the increase in surface tension induced by drugs through
augmentation of the rate of internalisation of membrane, such that an increase in the surface tension
of about 2% can be dissipated within 4.5 s. It is thus conclusive that pinocytosis is the biological
mechanism that protects Pgp, and is required to maintain MDR in cancer chemotherapy and CNS drug
impermeability at the BBB.
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